Christina Baik, MD, MPH, shares insight on the efficacy and safety of HER3-DXs in EGFR-inhibitor resistant, EGFR-mutated NSCLC.
Michael Schweizer, MD, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
Experts determine the Role of CD10 expression in endometriosis-associated mesenchymal stem cells on the progression of endometriosis-associated carcinoma, presented at the 2021 ASCO Annual Meeting.
David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA+, advanced, relapsed ovarian carcinoma.
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
INVICTUS study results reveal intra-patient dose escalation (IPDE) of ripretinib after disease progression indicate clinical benefit and tolerability in patients with advanced gastrointestinal…
Efstathios Kastritis, MD, shares findings from the ANDROMEDA study of subcutaneous daratumumab plus standard therapy for AL amyloidosis.
Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Stay in the know.
OncNet Newsletter